6
MICHAEL FARRAH and ARCHIEBOLD MANASSEH

Bambia System V.1 #Medicine

Embed Size (px)

Citation preview

Page 1: Bambia System V.1 #Medicine

MICHAEL FARRAH

and

ARCHIEBOLD MANASSEH

Page 2: Bambia System V.1 #Medicine

Counterfeit Drugs in Kenya, EAC and Africa in general

In Kenya counterfeit drugs represent up to 40%of the drugs circulating the market valued at USD 130 million annually.

EAC reports US. 500million unpaid taxes as a result of counterfeit goods. Tanzania reports loosing USD 370 – 617 due to tax evasion in relation to counterfeit goods.

More than 1/3 of Nigeria pharmaceuticals operations capacity is dominated by illegal producers.

THE PROBLEM

Page 3: Bambia System V.1 #Medicine

1. The KFDA mainly uses chemical means to discover counterfeits which is cumbersome and time consuming

2. Apps like OrigiCheck which only carter to smartphone users

3. Websites like fightthefakes.org which only caters to users who can access the internet

CURRENT STRATEGIES

WHAT WE WANT TO DOEmpowering consumers in the fight against counterfeit medicine.

Page 4: Bambia System V.1 #Medicine

OUR SOLUTION BAMBIA will have a USSD service which is meant to

counteract counterfeit medicine by matching reference numbers of

circulating drugs and those registered by the KFDA

Page 5: Bambia System V.1 #Medicine

Safaricom Airtel Orange Equitel

Welcome to BAMBIA1.Enter code

OK/ENTER

Safaricom Airtel Orange Equitel

X.1234

OK/ENTER

Safaricom Airtel Orange Equitel

Welcome to BAMBIA1. Enter Code2. EnquirePress respective digit then OK/ENTER

Product X, No. 1234

#genuineBambia Thank You

Safaricom Airtel Orange Equitel

Welcome to BAMBIA1. Enter Code2. EnquirePress respective digit then OK/ENTER

Product Y, No. 4321

#notgenuine

Bambia Thank You

HOW

WORKSSafaricom Airtel Orange Equitel

*USSD CODE#

THIS REFERENCE NUMBER IS MATCHED BY AN ALREADY ESTABLISHED DATABASE OF REGISTERED DRUGS FROM THE KFDA

OR

Page 6: Bambia System V.1 #Medicine

HOW WILL WE MAKE MONEY

BAMBIA will be a freemium product to the consumers (patients)

It will be a subscription product to the producers/licencees/ regulators e.g KEBS who will pay monthly for the information that we send them.